# A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line

> **NCT04764487** · PHASE3 · UNKNOWN · sponsor: **Weprom** · enrollment: 178 (estimated)

## Conditions studied

- Renal Cell Carcinoma Metastatic

## Interventions

- **DEVICE:** KidneyPRO
- **OTHER:** standard follow-up

## Key facts

- **NCT ID:** NCT04764487
- **Lead sponsor:** Weprom
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-07
- **Primary completion:** 2023-06-07
- **Final completion:** 2025-06-15
- **Target enrollment:** 178 (ESTIMATED)
- **Last updated:** 2022-05-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04764487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04764487, "A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04764487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*